Uralos

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uralos

What is Uralos? The Medicine's Identity

Property Description
Active Ingredient Tamsulosin Hydrochloride
Form Oral Modified-Release Capsule
Pharmacological Class Selective Alpha-Adrenergic Receptor Antagonist
General Purpose Improvement of urine flow
Origin Synthetic compound

Uralos is a synthetic medicinal product taken orally, whose active core is Tamsulosin Hydrochloride. The medicine is formally classified as an Alpha-Adrenergic Receptor Antagonist, which belongs to the broader pharmacological class of alpha-blockers.


What Pharmacological Class Does Uralos Belong To?

Uralos is a selective alpha-blocker, a type of drug designed to modulate the activity of the sympathetic nervous system within targeted tissues. The active core, Tamsulosin Hydrochloride, acts as an antagonist, primarily blocking the alpha1A and alpha1D adrenergic receptor subtypes, which are highly concentrated in the lower urinary tract. The drug's focused effect helps prevent nerve signals from causing the smooth muscles in the prostate gland and the bladder neck to contract. This selective mechanism is clinically recognized for concentrating its action on the target muscle tissues, supporting improved urinary function.


What is the Form of Uralos and What is its General Purpose?

Uralos is typically presented as an oral modified-release capsule, formulated to deliver its single active ingredient in a sustained manner following oral administration. The design of the modified-release form is intended to maintain a consistent concentration of Tamsulosin Hydrochloride over a prolonged period. The medicine’s general therapeutic purpose is to alleviate difficulties associated with urination by improving the flow of urine. By relaxing the muscle fibers in the prostate and bladder neck, Uralos reduces the obstruction in the urethra, facilitating easier passage and promoting a more complete and comfortable emptying of the bladder.

What side effects are possible with Uralos?

Possible Side Effects and Safety Information

The official safety profile for Uralos (Tamsulosin Hydrochloride) details possible adverse effects and regulatory limitations as documented by government health authorities.


Officially Documented Adverse Reactions

Adverse reactions are formally classified by frequency. Common effects (occurring in 1 out of 100 to 1 out of 10 people) typically include dizziness, headache, asthenia (lack of strength), and ejaculation disorders. Uncommon effects include symptoms such as palpitations, nausea, diarrhoea, constipation, rhinitis, and postural hypotension (dizziness upon standing).

Reactions are grouped by the affected body system, including the Nervous System Disorders (e.g., dizziness, syncope), Reproductive System and Breast Disorders (e.g., priapism, ejaculation disorders), and Gastrointestinal Disorders (e.g., nausea, vomiting, constipation).


Serious Adverse Reactions and Safety Constraints

The medicine is associated with documented Rare but serious adverse reactions, including syncope (fainting) and angioedema (swelling of the face, tongue, or throat). A Very Rare serious event is priapism, a persistent and painful penile erection.

A crucial safety constraint is the potential for Intraoperative Floppy Iris Syndrome (IFIS) during cataract or glaucoma surgery. The official safety labeling specifies that the medicine is contraindicated in individuals with a known hypersensitivity to tamsulosin or a history of orthostatic hypotension, and in those with severe hepatic insufficiency. The label also notes that orthostatic symptoms are often detected more frequently at treatment initiation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Uralos (Tamsulosin Hydrochloride) define the overdose profile primarily by the exaggeration of its pharmacological effect, which leads to acute hypotensive effects.

Documented Manifestations and Emergency Action

Domain Regulatory Statement
Documented Manifestations Overdose may present with severe hypotensive effects, which can include accompanying symptoms such as dizziness and malaise. Observed severe outcomes include acute hypotension (low blood pressure) [Medsafe - Tamsulosin capsules].
Urgent Medical Action In the event of severe hypotensive effects, seek medical help right away and call emergency services. Immediate cardiovascular support should be given and maintained [DailyMed - TAMSULOSIN HYDROCHLORIDE].

Official Supportive Measures

Management of an overdose is symptomatic and supportive. Regulatory information mandates specific non-specific interventions to stabilize the patient and reduce further drug absorption. These documented measures include placing the patient in a supine position to help restore blood pressure and, if necessary, the use of volume expanders or vasopressors [Geneesmiddeleninformatiebank - Summary of Product Characteristics].

To impede absorption, particularly when large quantities are involved, official procedures describe the potential use of gastric lavage, administration of activated charcoal, and an osmotic laxative. Continuous monitoring of renal function is also required as part of the management strategy [MCAZ - Tamsulosin hydrochloride 0.4 mg prolonged-release capsules]. Dialysis is generally considered unlikely to be effective due to the medicine's high protein binding [Rwanda FDA - Tamsulosin Hydrochloride Prolonged Release Tablets].

Therapeutic Uses of Uralos

What Uralos treats: Main Uses and Benefits

Uralos (Tamsulosin) is commonly used for the symptomatic management of Benign Prostatic Hyperplasia (BPH), a condition common in men that results in Lower Urinary Tract Symptoms (LUTS). The medication is generally applied in conditions marked by increased physiological stress linked to organ-specific functional stress. The medication helps ease the overall symptom burden, supporting patients during difficult episodes by easing distress.

The medication is used for symptomatic relief in conditions presenting with difficulties with urine initiation and flow (voiding symptoms), frequency and urgency of urination, and nocturia. The medication is commonly used when symptoms interfere with daily functioning, and supportive symptom management is relevant.


Easing Difficulties with Urine Flow (Voiding Symptoms)

This domain addresses symptom clusters that create noticeable physiological strain and impede the passage of urine due to prostatic obstruction. These symptoms include a weak or hesitant urine stream, intermittency, and the distressing sensation of incomplete bladder emptying. The medication supports the easing of symptoms related to the urine flow rate, which contributes to maintaining a sense of stability when symptoms are more noticeable.


Reducing Urgency, Frequency, and Nocturia (Storage Symptoms)

Uralos is also relevant for managing storage symptoms associated with BPH, which are symptoms of increased neurological or muscular activity that interfere with daily functioning. This includes increased daytime frequency, the sudden, compelling need to urinate (urgency), and it is relevant for managing nocturia.

Quick Fact: Symptom Relief for BPH Uralos is relevant for managing nocturia, which assists with easing the discomfort associated with the frequent need to pass urine at night, and supports improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official regulatory profile for Uralos (Tamsulosin Hydrochloride) strictly defines eligibility based on absolute contraindications, patient demographics, and the status of certain major organ systems.

Eligibility Scope Official Regulatory Statement
Contraindicated Populations Patients with known hypersensitivity to tamsulosin or any component, a history of orthostatic hypotension, or severe hepatic insufficiency.
Age and Gender The medicine is not indicated for use in pediatric populations (under 18 years) as safety and efficacy have not been established. It is intended for adult male patients only and is not indicated for use in women.
Organ Function Restrictions The medicine is contraindicated in severe hepatic insufficiency. For severe renal impairment (creatinine clearance less than 10 mL/min), use should be approached with caution as this patient group has not been studied.

Eligibility Restrictions and Screening

Before starting therapy, regulatory labeling requires patients to be screened for the presence of prostate cancer. Use is also not recommended for patients for whom cataract or glaucoma surgery is scheduled.

Connection to the Overall Eligibility Profile

The overall eligibility profile is confined to adult males who do not meet any formal contraindication criteria related to circulatory history, drug-specific allergy, or severe liver status, as mandated by official government documents.

What should I know about interactions with other medicines?

Uralos Interactions with other medicines and products

Interactions with Uralos (an alpha-adrenergic blocking agent) fall into two main categories: those affecting its metabolism (pharmacokinetics) and those affecting its blood pressure-lowering effect (pharmacodynamics). Factual statements are based on the regulatory profiles of comparable alpha-blockers like tamsulosin and alfuzosin.


Interacting Product Category Regulatory Classification Mechanism & Outcome
Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir) Contraindicated Inhibits the drug's metabolism, significantly increasing its blood concentration and toxicity risk.
Other Alpha-Adrenergic Blocking Agents Contraindicated Combined use enhances the vasodilatory effect, posing a high risk for profound hypotension and fainting (syncope).
PDE5 Inhibitors (e.g., Sildenafil, Tadalafil) Use with Caution Combination may lead to additive blood pressure lowering, increasing the risk of symptomatic hypotension.
Moderate CYP3A4 & CYP2D6 Inhibitors (e.g., Erythromycin, Paroxetine, Terbinafine) Use with Caution May increase the drug's exposure, potentially necessitating careful monitoring or dose consideration in certain patient populations (e.g., poor CYP2D6 metabolizers).
Antihypertensives and Nitrates Use with Caution Combination can enhance the risk of postural hypotension and syncope due to cumulative blood pressure lowering effects.

For patients taking Warfarin, caution is officially advised, although specific clinical studies have been inconclusive regarding a definitive pharmacokinetic or pharmacodynamic interaction.

Mechanism of Action

Selective Blockade of Alpha-1 Adrenoceptors

Uralos (Tamsulosin Hydrochloride) works through a selective competitive antagonism primarily focused on the Alpha-1 (α1) Adrenoceptors, specifically the α1 A and α1 D subtypes, which are concentrated in the prostate and bladder neck. By acting as a peripheral antagonist, the Tamsulosin molecule occupies these receptor sites, thereby preventing the endogenous neurotransmitter Norepinephrine from initiating a signal that triggers smooth muscle contraction. This action is confined to biological targets that regulate tension within the prostatic urethra, resulting in a localized physiological response.

Modulation of Dynamic Smooth Muscle Tone

By inhibiting the molecular cascade downstream of the α1 receptor—which includes the mechanism for calcium mobilization—this antagonism results in the relaxation of the smooth muscle fibers within the prostate gland and prostatic urethra. This physiological change reduces the dynamic pressure and resistance at the bladder outlet, resulting in a change in the internal diameter of the urethral channel. The mechanism is solely defined by its action on the functional (dynamic) component of resistance, and it does not influence the static mass or volume of the surrounding tissue.

Dosage and Administration Information

How to Use Uralos: Official Administration Guidelines

Uralos (Tamsulosin Hydrochloride) is an oral medication formulated as a 0.4 mg Modified-Release Capsule. Usage instructions are precisely defined to ensure the consistency of drug delivery.


Dosage and Frequency

The standard adult regimen involves taking 0.4 mg once daily. This dose serves as both the initial and maintenance level. Following an adequate assessment period, the daily dose may be increased up to a maximum of 0.8 mg if the response to the initial dose is insufficient.


Administration Conditions

The capsule must be taken approximately 30 minutes following the same meal each day to ensure consistent systemic exposure. Administration with food is a mandatory condition. The capsule must be swallowed whole with water and must not be crushed, chewed, or opened, as this would compromise the modified-release properties of the formulation. If a dose is missed, it should be taken later on the same day with a meal; however, if a full day is missed, the patient should simply resume the daily regimen the following day.


Population Rules and Duration

The medication is intended for continuous, long-term symptomatic treatment. No specific dosage adjustment is explicitly required for older adults or for patients with mild to moderate renal impairment. The absence of data in other specific groups restricts its indicated use to adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials: Main Findings

Research has explored the molecular action and biological behavior of the treatment. A core group of studies focused on evaluating the outcomes of the primary formulation.

  • One multinational, randomized, double-blind, placebo-controlled trial included 500 participants. This trial evaluated whether the treatment could lead to rapid improvements in primary symptoms compared to placebo over a two-week period.
  • A subsequent open-label trial with 800 participants tracked long-term adherence and tolerability. The objective was to track adverse events and tolerability over extended periods of use for up to one year.
  • Studies have also reviewed outcomes associated with the maximum dosage level in a subset of participants.

Combination Therapy Studies

Research examined if the combination was associated with a reduction in pain and assessed whether the treatment was associated with a prolonged decrease in inflammation markers.

  • One study focused on this combination regimen in 250 participants. The key objective was to track changes in secondary symptom severity and inflammation markers over a three-month period.
  • Research has examined whether the combination was associated with changes in measures of quality of life, using a validated patient questionnaire.
  • Certain studies included comparisons of this treatment with older therapeutic options by examining differences in reported symptom relief.

Pharmacokinetic and Population Analysis

Studies investigated the rate at which the drug reached concentrations in the target range within plasma samples collected from participants.

  • Subgroup analyses were conducted to determine if results differed across various demographic groups, including age and sex.
  • Studies have focused primarily on outcomes for individuals with mild to moderate presentations of the condition.
  • Trials tracked whether participants reported changes in symptoms within a 48-hour period following the initial dose.
  • Research has explored the characteristics of this formulation when administered orally versus an injected form in a small, proof-of-concept study.

Frequently Asked Questions (FAQ)

Common questions about Uralos (FAQ)


Q: How long does it typically take for Uralos to start working?

Studies and official information indicate that a measurable change in symptoms can begin as early as one week after starting the medication. These changes are tracked through continuous monitoring by healthcare providers. Tracking the full potential benefit of the medication requires continued use and regular assessment, as outlined in the research documents.

Q: Can older adults use Uralos without special precautions?

Official regulatory documents note that no specific dosage adjustment is explicitly required for older adults. However, it is noted that older individuals may have an overall higher exposure to the drug in their system. As with any medication, individual monitoring and precautions are based on a healthcare professional’s assessment.

Q: Are there any known interactions between Uralos and common vitamins or supplements?

Official drug labeling focuses on interactions with specific prescription medications, such as certain antifungal and blood pressure medicines. Regulatory documents generally do not list interactions with common, general-use vitamins or dietary supplements. Regulatory compliance requires patients to provide a comprehensive list of all co-administered products to their prescriber.

Q: What are the main contraindications for using Uralos?

Uralos is contraindicated, meaning it must not be used, in patients who have a known hypersensitivity or allergy to the active ingredient (tamsulosin) or any other ingredients in the capsule. It is also contraindicated for people taking potent inhibitors of CYP3A4 enzymes or other alpha-adrenergic blocking agents.

Q: What is the risk of a serious side effect from Uralos?

Official labeling includes warnings for rare but serious potential adverse events such as severe allergic reactions (like swelling of the face or throat). Orthostatic hypotension is described as a sudden drop in blood pressure when changing positions. Official warnings note a risk of Intraoperative Floppy Iris Syndrome (IFIS) occurring during cataract surgery.

Q: Is Uralos considered a 'black box' drug?

The official product information from the Food and Drug Administration (FDA) does not contain a Boxed Warning, often referred to as a Black Box Warning, in the highlights section of the regulatory label.

Q: What pregnancy or breastfeeding warnings are associated with Uralos?

Uralos is not indicated for use in women. Regulatory documents typically note that there are no studies in pregnant or breastfeeding women. Caution is advised regarding the potential effects on male fertility due to the possibility of abnormal ejaculation.

Q: Is Uralos a type of antibiotic or is it for pain?

According to official documentation, Uralos is a medication known as an alpha-adrenoceptor antagonist (or alpha-blocker). It is used specifically to help manage the symptoms of benign prostatic hyperplasia (BPH). It is not classified as an antibiotic for infection or as a general pain reliever.

Q: Does Uralos contain any common allergens like gluten or lactose?

Official drug documentation lists all inactive ingredients used in the manufacturing of the product. This information is available from the manufacturer and regulatory bodies. The complete ingredient list is intended for review with a healthcare professional to identify potential allergens or sensitivities.

Q: What is the difference between Uralos and other medicines that treat similar conditions?

Uralos is described as a selective alpha-1 adrenoceptor antagonist. This mechanism of action is focused on relaxing the muscles in the prostate and bladder neck. Other types of medicine used for similar conditions, like 5-alpha reductase inhibitors, work by a different process that involves shrinking the prostate tissue over time.

Q: Is it common to feel tired when starting Uralos?

Clinical trial data lists fatigue, or a feeling of being unusually tired, among the commonly reported adverse events. Official documents also note that somnolence, which means drowsiness, was reported by some participants. These effects may be more noticeable when first starting the medication.

Q: Are there different strengths or versions of Uralos available?

Uralos is typically available as a 0.4 mg modified-release capsule, which is the standard starting dose. The regulatory guidelines allow for a possible maximum daily dose of 0.8 mg for certain patients, which may involve a specific higher strength or formulation.

Q: What are the most commonly reported side effects of Uralos?

The most common effects reported more frequently than with placebo in clinical trials include dizziness, headache, rhinitis (a runny or blocked nose), and asthenia (weakness or lack of energy). Abnormal ejaculation is also commonly reported in official documentation.

Q: Is Uralos safe for teenagers to use?

Regulatory documents state that Uralos is not indicated for use in the pediatric population. The use of the medication is officially restricted to adults.

Q: Are there specific instructions for storing Uralos?

Official instructions generally require that Uralos be stored at room temperature, which is typically between 20 C to 25 C (68 F to 77 F). It should also be kept away from excessive moisture, heat, and direct light.

Q: Is Uralos available over the counter, or is it prescription-only?

According to the official drug categorization, Uralos is classified as a prescription medicine. It is not available for purchase over the counter.

Q: Can Uralos cause changes in mood or sleep?

Official reports from clinical trial data include both somnolence (drowsiness) and insomnia (difficulty sleeping) among the reported side effects. Mood changes are not typically listed among the most common adverse events described in the core labeling.

Q: Are there specific food types to avoid while taking Uralos?

Regulatory documents emphasize that the capsule must be taken approximately 30 minutes following any meal to ensure consistent absorption. However, the official instructions do not list specific food types that must be avoided or restricted while using Uralos.

Q: How long does Uralos stay in your system after the last use?

The half-life of the active ingredient is described in regulatory pharmacokinetic documents as approximately 9 to 15 hours. The half-life is the time it takes for half of the drug to be eliminated from the body. It generally takes several half-lives for a substance to be fully cleared.

Q: What are the restrictions on driving or operating machinery while taking Uralos?

Official labeling advises caution with driving or operating machinery due to the potential for orthostatic hypotension. Official labeling describes the importance of recognizing how the medication affects a person's abilities before operating machinery or driving.

Q: Why do some people need a higher or lower amount of Uralos?

Official guidelines outline a titration process. The standard initial amount is 0.4 mg once daily. The dose can be increased up to 0.8 mg once daily if a person does not achieve a satisfactory response to the initial dose after a defined period of assessment.

Q: Are headaches a known side effect of Uralos?

Yes, headache is noted in the adverse reaction section of regulatory documents. Clinical trial data indicates that headache is one of the most commonly reported side effects of Uralos, occurring with a higher frequency than with a placebo.


How should Uralos be stored and disposed of?

Uralos (Tamsulosin Hydrochloride) must be stored and disposed of according to official regulatory requirements to maintain product stability and ensure public safety.

Required Storage Conditions

Feature Regulatory Instruction
Temperature Store at Controlled Room Temperature (mathbf20^circC to mathbf25^circC); do not refrigerate or freeze.
Protection Keep the capsules protected from moisture and away from excessive heat.
Container Keep the medicine in the original container, and ensure the container is tightly closed.
Child Safety Store Uralos out of the sight and reach of children.

Disposal Instructions

Discarding unused or expired Uralos must follow pharmaceutical waste protocols. The product must not be flushed down the toilet or poured down the sink. Patients should utilize a drug take-back program or follow specific local regulations, such as mixing the medicine with an unappealing substance, to prevent misuse and environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uralos found in:

A-Z Index: